Synteract Launches Rare Disease Institute
Estimand Framework: What it is and Why You Need it
With the final approval and release of ICH E9 (R1), clinical trial sponsors should prepare to include estimands in their protocols as well as their statistical design documents and study reports.
Clinerion Partners with Wefight
Tufts CSDD Study Reveals Increased External Data Sources Contributing to Delays in Trial Completion
Science 37 Introduces Native Support for iOS and Android
Science 37 Introduces Native Support for Apple and Android
Crucial Data Solutions Announces Updates to TrialKit AI
Raremark Partners With TriNetX
Europe Claims “Leading Role” in Combating COVID19
With the coronavirus now spread across northern Italy, the EU is assembling its forces to slow the virus with an aid package worth $250 million.
Medable Forms Patient Advisory Council
Parexel Announces Acquisition Model Answers
Virus Spread Threatens Clinical Research
Sponsors conducting trials in China are facing delays, while efforts to test potential antivirals and vaccines against COVID-19 are having enrollment difficulties.
Ease the Age Barrier That Keeps Young Cancer Patients Out of Trials
Teenagers with cancer could benefit from a recommendation to lower the age barrier so they can take part in clinical trials says a proposal from the Fostering Age Inclusive Research Trials Initiative.
Addressing the Immunogenicity Challenge
How modeling and simulation technology can predict and better manage immunogenicity, a key challenge for biologics drug development.
Latest People and Business News
The latest happenings in the industry, all in one place.
IQVIA Global Compliance Releases 3 New Tools
The Open Wearables Initiative Soliciting Algorithms and Datasets
My 2020 Data Resolutions
While “Big Data” is a great buzzword in management circles, small data (with big problems) never gets much attention.
NUVISAN and Bayer Create New Research Unit in Berlin
To Extrapolate Site Enrollment or Not To Extrapolate? That is the Question.
Analysis of over 330,000 Phesi trial protocols shows predicting future enrollment performance by extrapolating data is flawed.
